Skip to main content

Share story

AI Products

EssilorLuxottica and SAP test smart glasses linked to retail systems

EssilorLuxottica and SAP test smart glasses linked to retail systems Image: Primary
EssilorLuxottica and SAP are testing smart-glasses applications that let store associates and field technicians retrieve information from SAP business systems by voice. A demonstration used the glasses to identify a returning customer, obtain purchase history, reorder products and suggest add-ons using customer and purchase context. The prototypes connect SAP's Joule artificial-intelligence software with EssilorLuxottica's retail systems, which support 15,000 stores. The companies developed the two initial applications in two weeks and are targeting commercialization by year-end. They remain in testing, and the source provides no deployment results from stores or field operations.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from SAP News Center and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...